Patents Examined by Kristin Larson
  • Patent number: 5422264
    Abstract: A method for growing epithelial cells in vitro using soluble proteins secreted by 804G rat bladder carcinoma cells. These proteins are able to stimulate cell attachment and hemidesmosome formation in cells grown in contact with the proteins. The purification of these proteins from 804G culture supernatant is greatly facilitated by culturing the cells under low serum conditions.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: June 6, 1995
    Assignee: Desmos, Inc.
    Inventors: Vito Quaranta, Marketta Hormia
  • Patent number: 5415858
    Abstract: A non-sporeforming enteric-type bacterium elaborates a regulatory substance that interacts with the insect's own neuro-secretory regulatory system at the time when the larvae of (holometamorphic) insects reach the prepupal stage. This bacterium is used to inhibit or interfere with the synthesis of chitin whereupon the affected insects are unable to complete their life cycle and die while at an immature stage.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: May 16, 1995
    Inventor: Paul Surany
  • Patent number: 5413785
    Abstract: A method is provided for reducing the quantity of endotoxin circulating in the blood plasma of a living subject affected by an endotoxin-mediated clinical state. The method employs a formulated preparation comprising at least one persistent, acid-resistant, and colonizing Lactobacillus species in combination with a biocompatible carrier. The user then introduces the formulated preparation to the gastrointestinal tract of the subject on one or on multiple occasions.
    Type: Grant
    Filed: March 3, 1994
    Date of Patent: May 9, 1995
    Assignee: New England Deaconess Hospital Corp.
    Inventor: Amin A. Nanji
  • Patent number: 5413919
    Abstract: A method for preparing a thromboplastin reagent from cultured human cells comprising the steps of washing the cells with isotonic aqueous salt solution, lysing the cells by hypotonic shock, and resuspending the cell lysate in a diluent compatible with a one-stage prothrombin time determination to reach a concentration of about 0.5 to 3.0 mg/mL thromboplastin, whereby the cell lysate thromboplastin suspension produces a clot in a one stage prothrombin time test in about 10 to 15 seconds, with a mean normal prothrombin time of about 11-13 seconds, when added to citrated normal plasma in a volume ratio of about 2:1, such thromboplastin reagent being stable for at least 8 hours at 37.degree. C. and for at least 5 days at 4.degree. C.
    Type: Grant
    Filed: June 21, 1994
    Date of Patent: May 9, 1995
    Assignee: Akzo N.V.
    Inventors: Ray F. Ebert, Rafael P. Valdes-Camin
  • Patent number: 5411885
    Abstract: Methods of embedding and culturing tissue employing a fibrin glue composition of 2 to 100 mg/ml fibrinogen, 1 to 200 U/ml fibrinogen-activating enzyme, and 1 to 30 mM Ca(II) compound, are disclosed.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: May 2, 1995
    Assignee: New York Blood Center, Inc.
    Inventor: Gerard Marx
  • Patent number: 5409699
    Abstract: The invention is a pharmaceutical composition containing a glycosylated protein having human tissue type plasminogen activator activity of at least 1.4 MU/ml, citrate, and at least one of a number of various compounds. The composition has a pH ranging from 4.5 to 9.
    Type: Grant
    Filed: July 19, 1991
    Date of Patent: April 25, 1995
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ulrich Kohnert, Rainer Rudolph
  • Patent number: 5407672
    Abstract: L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan.
    Type: Grant
    Filed: April 8, 1993
    Date of Patent: April 18, 1995
    Assignees: Cornell Research Foundation, Inc., Duke University
    Inventors: Owen W. Griffith, Henry S. Friedman
  • Patent number: 5407673
    Abstract: Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of any intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: April 18, 1995
    Assignee: Orion Therapeutic Systems, Inc.
    Inventors: Edward Reich, Thomas G. Easton
  • Patent number: 5405772
    Abstract: A serum-free or serum-depleted medium for the short- and long-term proliferation and development of cells, particularly hematopoietic cells and bone marrow stromal cells, the medium comprising cell proliferation and development effective amounts of:a standard culture medium such as Iscove's modified Dulbecco's medium; serum albumin; transferrin; a source of lipids and fatty acids; cholesterol; a reducing agent; pyruvate; a glucocorticoid (when the cells to be cultured are hematopoietic cells); nucleosides for synthesis of DNA and RNA; growth factors that stimulate the proliferation and development of stromal cells and cells from a variety of tissues or organs, such as epidermal growth factor, fibroblast growth factor, platelet derived growth factor, and insulin; and extracellular matrix materials, such as collagen, fibronectin, and laminin.
    Type: Grant
    Filed: June 18, 1993
    Date of Patent: April 11, 1995
    Assignee: Amgen Inc.
    Inventor: Ian L. O. Ponting
  • Patent number: 5405607
    Abstract: A process and apparatus for one-step preparation of the fibrinogen component of an adhesive is described. The fibrinogen is precipitated directly from plasma using polyethylene glycol. This permits preparation of autologous fibrinogen from the patient during surgery which can be combined with calcium, ion and thrombin and used as an adhesive.
    Type: Grant
    Filed: July 12, 1993
    Date of Patent: April 11, 1995
    Inventor: Gordon H. Epstein
  • Patent number: 5401655
    Abstract: A process for biologically preventing dicotyledonous plant diseases which comprises: cutting a seedling of a dicotyledon which includes the seedling between a cotyledon and less than three leaves at a growth stage; immersing the upper portion of the cut seedling into a symbiotical bacteria suspension having antifungal and antibacterial activities and induced resistance to plant pathogens in order to inoculate the symbiotical bacteria into interior tissues in the vessel and intercellular space of the dicotyledonous plants; cutting the seedlings in a nursery bed or directly planting them in a field for further association of the symbiotical bacteria; and preventing dicotyledonous plant diseases of the dicotyledonous plants.
    Type: Grant
    Filed: February 17, 1993
    Date of Patent: March 28, 1995
    Assignee: Tochigi Prefecture
    Inventors: Toshio Kijima, Sadao Yonai, Kazuo Oohashi, Masayuki Amagai
  • Patent number: 5393666
    Abstract: There is disclosed a method of activating prothrombin by means of trypsin, wherein the prothrombin is recovered from a blood or plasma fraction, treated with trypsin immobilized on a water-insoluble carrier, and separated from the immobilized trypsin after activation.
    Type: Grant
    Filed: March 19, 1993
    Date of Patent: February 28, 1995
    Assignee: Immuno Aktiengesellschaft
    Inventor: Yendra Linnau
  • Patent number: 5386027
    Abstract: A carbohydrate receptor for pathogenic bacteria is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The receptor can be included in a composition having a pharmaceutically acceptable carrier. The receptor may be used for purifying, detecting, or removing bacteria from diseased tissue. The structure of the receptor is N-acetylagalctosamine-beta-1-4-galactose-beta-1-4-glucose, abbreviated GalNAc.beta.1-4Gal.beta.1-4Glc. The receptor is present in human and animal tissues as complex molecule and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GM1, asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.
    Type: Grant
    Filed: May 13, 1993
    Date of Patent: January 31, 1995
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Howard C. Krivan, Victor Ginsburg, David D. Roberts
  • Patent number: 5366730
    Abstract: Pharmaceutical preparation of a protein with t-PA activity with an enzymatic activity of at least 0.25 MU/ml. and a pH value of 4.5 to 9 which contains a substance of the group citric acid, ascorbic acid, 2-oxoglutaric acid, fumaric acid, Tris and EDTA in a concentration of at least 0.2 mole/l., as well as a medicament based on a protein with t-PA activity and processes for its preparation.
    Type: Grant
    Filed: April 6, 1993
    Date of Patent: November 22, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ulrich Kohnert, Rainer Rudolph
  • Patent number: 5354671
    Abstract: A novel enzyme composition capable of lysing or digesting cells or cellular debris of polysaccharide-producing bacteria in the presence of the exopolysaccharides without any significant degradation of the exopolysaccharides. Methods for preparing the enzyme composition, using the composition to clarify mixtures of polysaccharides and cellular debris, and pure cultures for making the enzyme are disclosed.
    Type: Grant
    Filed: June 26, 1992
    Date of Patent: October 11, 1994
    Assignees: Shin-Etsu Chemical Co., Ltd., Shin-Etsu Bio, Inc.
    Inventor: Thomas J. Pollock
  • Patent number: 5324647
    Abstract: Surfaces of polymeric materials are coated with a layer of thermally denatured fibrinogen. The fibrinogen may be treated with thrombin to produce fibrin, and additional fibrinogen and factor XIII added to produce a cross-linked fibrin coating. The resulting coated surface is stable, anti-thrombotic and resistant to platelet adhesion. Polymeric materials coated in this way are useful in constructing vascular grafts and prosthetic devices, and provide test systems useful in the study of thrombogenesis.
    Type: Grant
    Filed: September 14, 1993
    Date of Patent: June 28, 1994
    Assignees: McMaster University, ZymoGenetics, Inc.
    Inventors: Fraser D. Rubens, Paul D. Bishop
  • Patent number: 5324514
    Abstract: Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, treating impaired liver function, treating cystic fibrosis, regulating the absorption of dietary cholesterol, and for dissolving gallstones by administering the compositions to a mammal in need of such treatment.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: June 28, 1994
    Assignee: Digestive Care Inc.
    Inventor: Tibor Sipos
  • Patent number: 5324629
    Abstract: A method for improving recovery of cells from liquid suspension by centrifugation. The method comprises coating the interior of centrifuge containers with a solution comprising an amphipathic compound prior to introduction of the cell suspension and centrifugation. The method is particularly suited for recovery or concentration of rare cells from dilute suspensions, for example when rare cells are isolated from a sample by sorting on a flow cytometer.
    Type: Grant
    Filed: April 27, 1993
    Date of Patent: June 28, 1994
    Assignee: Becton, Dickinson and Company
    Inventors: Janette T. Phi-Wilson, Diether J. Recktenwald
  • Patent number: 5322780
    Abstract: A process for production of omega 9 type polyunsaturated fatty acid or a lipid containing the fatty acid, comprising the steps of culturing a microorganism having an ability to produce omega 9 type polyunsaturated fatty acid or a lipid containing said fatty said, and recovering the omega 9 type polyunsaturated fatty acid or the lipid containing said fatty acid.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: June 21, 1994
    Assignee: Suntory Limited
    Inventors: Hiroshi Kawashima, Hideaki Yamada, Sakayu Shimizu
  • Patent number: 5320961
    Abstract: A method for asexual in vitro propagation of corn plants is described. The plant tissue (shoot tips or apices) are differentiated with 2,4-dichlorophenoxy acetic acid (2,4-D) and N.sup.6 -benzyladenine (BA) and mixtures thereof and then the differentiated tissue is grown in indole-3-butyric acid (IBA) to produce the corn plant which is fertile.
    Type: Grant
    Filed: November 16, 1992
    Date of Patent: June 14, 1994
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Heng Zhong, Masomeh B. Sticklen, Chinnathambi Srinivasan